Attachment #2 Overview of Follow-up

Similar documents
Attachment #2 Overview of Follow-up

Cystectomies and bladder preservation: What you need to know

Appendix 4 Urology Care Pathways

Chemotherapy Treatment Algorithms for Urology Cancer

Urologic Oncology Section

A schematic of the rectal probe in contact with the prostate is show in this diagram.

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

BLADDER CANCER: PATIENT INFORMATION

Bladder Cancer Guidelines

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Male genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital.

Treatment Testicular Cancer Guidelines

THE UROLOGY GROUP

Glossary of Terms Primary Urethral Cancer

Surveillance after Treatment of Malignancies. John M. Burke, M.D. March 2013

UROLOGICAL CANCER 2010 COMPARATIVE AUDIT REPORT

BLADDER HEALTH. Muscle Invasive Bladder Cancer: A Patient Guide

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MEDitorial March Bladder Cancer

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

3.1 Investigations for Patients Presenting with Haematuria Table 1

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

DEPARTMENT OF ONCOLOGY ELECTIVE

Upper Tract Urothelial Carcinomas (UTUCs)

GUIDELINES ON TESTICULAR CANCER

Pathology Driving Decisions

Case 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:

UNDERSTANDING BLADDER CANCER

A patient with recurrent bladder cancer presents with the following history:

UROLOGY CANCER 2009 COMPARATIVE AUDIT REPORT

When to Integrate Surgery for Metatstatic Urothelial Cancers

BLADDER CANCER CONTENT CREATED BY. Learn more at

Part II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by

Staging and Grading Last Updated Friday, 14 November 2008

Exercise. Discharge Summary

Bladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist

Bladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope

Cancer Cases Treated and Results

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Highlighting Clinical Trials Muscle Invasive Bladder Cancer

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

Neoplasms of the Prostate and Bladder

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

Trimodality Therapy for Muscle Invasive Bladder Cancer

Quiz. b. 4 High grade c. 9 Unknown

Bladder Cancer Basics For the Newly Diagnosed

Arieh L. Shalhav Is There a Risk in Robotic Nephroureterectomy?

SAMPLING OF POST NEPHRECTOMY CANCER CARE (5)

Comparative Analysis of Stage and Other Prognostic Factors Among Urethral, Ureteral, and Renal Pelvis Malignant Tumors

Quiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.

AUA Guidelines for Invasive Bladder Cancer: What s New?

Section Activity Activity Description Details Reference(s)

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Cancer Program Report 2014

Guidelines for the Management of Bladder Cancer

Open clinical uro-oncology trials in Canada

COLON CANCER CARE GUIDELINES NON-METASTATIC DISEASE

What is endometrial cancer?

Carcinoma of the Renal Pelvis and Ureter Histopathology

Open clinical uro-oncology trials in Canada

Information for Patients. Bladder Cancer. English

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends

Open clinical uro-oncology trials in Canada

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

ESMO Consensus Empfehlungen 2017

Clinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Doppler ultrasound of the abdomen and pelvis, and color Doppler

Testicular Cancer. Regional Follow-up Guidelines

KIDNEY HEALTH. Kidney Masses and Localized Kidney Tumors: A Patient Guide

Prostate Overview Quiz

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.

AllinaHealthSystems 1

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer

Surveillance Strategies in Kidney Cancer: When is Enough? Role of Survivorship Clinic in Long-Term Follow-Up of Kidney Cancer

We are gong to focus on: Unit 9. Before we begin: Chronic Renal Failure/Uremia ESRD/Dialysis Prostate Cancer Testicular Cancer Renal Cancer

Procedure Specific Information Sheet Open Radical Prostatectomy

Collection of Recorded Radiotherapy Seminars

Kaiser Oakland Urology

Laparoscopic Surgery. The Da Vinci Robot. Limits of Laparoscopy. What Robotics Offers. Robotic Urologic Surgery: A New Era in Patient Care

6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).

Chemotherapy for Urological Cancers

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Muscle-invasive bladder cancer

General information about prostate cancer

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Haematuria Clinic. Information for patients Urology PROUD TO MAKE A DIFFERENCE SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Muscle-invasive bladder cancer

Cancer. University of Illinois at Chicago College of Nursing

The Selenium and Vitamin E Prevention Trial

Transcription:

Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer to home or with a primary care doctor. All tests should be sent to Dr. Pierorazio (or his office) by email, fax or mail. Dr. Pierorazio would like to see or speak to all patients one month following surgery to confirm recovery and wound healing. Contents Bladder cancer after radical cystectomy (Page 1) Kidney cancer after radical or partial nephrectomy (Page 2) Prostate cancer after radical prostatectomy (Page 3) Testicular cancer after orchiectomy or RPLND (Page 3) Upper tract urothelial cancer after nephroureterectomy (Page 4) BLADDER CANCER AFTER RADICAL CYSTECTOMY 3 weeks after surgery - Urinary conduit: exam by enterostomal nurse - Neobladder or Indiana Pouch -catheter removed, learn self-catheterization -if suprapublic catheter present, will be removed when comfortable with self-catheterization -referral to physical therapy (if neobladder or needed) After the first year, patients receiving neoadjuvant chemotherapy are recommended to undergo oncologic follow-up with their medical oncologist and see Dr. Pierorazio annually or sooner if issues. Low-Risk Bladder Cancer: Stage 0, Tis, or 1 Time After Surgery 6 12 24 CT scan Abdomen & x x Pelvis Chest -ray x x Blood Test (CBC, CMP, Folate, B12) x x High-Risk Bladder Cancer: Stage 2 or greater* Time After Surgery 4-6 12 18 24 30 Ct scan -ray Blood tests (CBC, CMP, Folate, B12) CBC: complete blood count, CMP: complete metabolic panel *This schedule may be modified on an individual basis or based on the medical oncologist s recommendations 1

KIDNEY CANCER AFTER PARTIAL OR RADICAL NEPHRECTOMY Risk is determined by the Stage (extent) of disease. In some circumstances, Grade (aggressiveness under the microscope) will modify risk. For example, any Grade IV tumor is high-risk. Low-Risk Kidney Cancer: Stage I (Cancer confined to the kidney, less than 7cm) Time After Surgery 1 month 6 12 2 Blood and Urine Tests (Kidney Function, CT scan (Abdomen and Pelvis) Chest -ray Optional Intermediate-Risk Kidney Cancer: Stage II (Cancer confined to the kidney, greater than 7cm) Time After Surgery 1 month 6 12 2 3 Blood and Urine Tests CT scan (Abdomen and Pelvis) Chest -ray Optional High-Risk Kidney Cancer: Stage III or Higher (Cancer outside of the kidney), or Grade IV at any stage Time After Surgery 1 month Every 2-6 12 18 24 * Blood and Urine Tests CT scan (abdomen and (Until Chest -ray (or Chest CT)* (Until (After *Frequency of recommended imaging is determined by patient characteristics and tumor pathology report. 2

PROSTATE CANCER 1 month after surgery for post-operative appointment After Radical Prostatectomy: Low Risk (Gleason 6, PSA <10, pt2) Time after surgery Year 1 After 1 year PSA At 6 and 12 After Radical Prostatectomy: Intermediate Risk (Gleason 7, PSA 10-20, pt3a) Time after surgery Year 1 Year 2-3 After 3 PSA Every 3 Every 6 After Radical prostatectomy: High Risk (Gleason 8-10, PSA >20, pt3b, N1 or positive surgical margins) Pending the pathology results, we will consider referrals to Medical and Radiation oncology as appropriate Time after surgery Year 1-2 After 2 PSA Every 3 TESTICULAR CANCER SEMINOMA Active Surveillance after Orchiectomy: Stage I (A or B) Seminoma Time after surgery Year 1 Year 2 3-5 After 5 Every 3 Every 6 Every 6 CT scan (abdomen +/- * Chest -ray Hormone Evaluation Every 6 (Option at 3 ) Every 6 Optional on annual basis Every 12 Every year Every 1-2 Every 1-2 NON-SEMINOMATOUS GERM CELL TUMORS (NSGCT) Active Surveillance after Orchiectomy Stage I (A or B) Non-seminomatous germ cell (NSGCT) Time after surgery Year 1 2 Year 3 4-5 After 5 Every 3 Every 6 Every year Every 1-2 CT scan (abdomen +/- * Chest -ray (Consider CT Chest once per year) IA: Every 6 (Option at 3 ) IB: Every 3 At 6 and 12 (1A); Every 3 (1B) Every 6 Once per year Every 6 Every 6-12 Every 1-2 Every 1-2 3

Hormone Evaluation * Abdominal MRI can replace Abdominal CT on an alternating basis, but MRI must be done at Johns Hopkins. After chemotherapy and/or radiation therapy: recommend follow-up per NCCN Guidelines. After Primary RPLND: No active cancer, no adjuvant chemotherapy If active cancer, the follow-up regimen will be determined after consideration of chemotherapy. Time after surgery 1-2 3-5 After 5 Every 3-4 Every 6 Every 1-2 CT scan (abdomen and At 3-4, 12 and 24 Chest -ray Hormone Evaluation After Post-chemotherapy RPLND: No active cancer or teratoma only If active cancer, the follow-up regimen will be determined after consideration of chemotherapy. Time after surgery 1-2 2-5 After 5 Every 3-4 Every 6 Every 1-2 CT scan (abdomen and At 3-4, 12 and 24 Chest -ray Hormone Evaluation For patients receiving chemotherapy with a complete response: follow-up is recommended to follow the NCCN Guidelines. UPPER TRACT UROTHELIAL CANCER (CANCER OF THE RENAL PELVIS OR URETER) AFTER NEPHROURETERECTOMY or URETERECTOMY After the first year, patients receiving chemotherapy are recommended to undergo oncologic follow-up (imaging) with their medical oncologist. Low-Risk Urothelial Carcinoma: Low-Grade, Non-Invasive (Stage 0 or 1) Time After Surgery Year 1 Year 2-3 Year 4-5 After 5 Blood and Urine Tests At 1, 6 and 12 CT scan (abdomen and At 6 and 12 4

Chest -ray At 6 and 12 Cystoscopy Every 3-4 Every 6 Every 1-2 High-Risk Urothelial Carcinoma: High-Grade or Invasive (Stage 2 or greater) or Positive Lymph Nodes with or without chemotherapy Time After Surgery Year 1 Year 2-3 Year 3-5 After 5 Blood and Urine Tests At 1, 6 and 12 Every 6 CT scan (abdomen and Every 3-4 Every 6 Chest -ray (or Chest CT) Every 6 Every 6 Cystoscopy Every 3-4 Every 6 Every 1-2 5